

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

APPOINTMENT OF AN EXECUTIVE DIRECTOR

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 2 March 2026, Mr. Zhang Yiwei (“**Mr. Zhang**”) has been appointed as an Executive Director of the Company.

Set out below are the biographical details of Mr. Zhang:

Mr. Zhang, aged 41, who joined the Group in February 2026 and currently serves as the Executive President of the Group, primarily responsible for the Group’s securities affairs. Prior to joining the Group, he possessed over 17 years of extensive experience in the investment banking industry, specialising in equity financing, debt financing, and mergers and acquisitions.

From July 2015 to January 2026, Mr. Zhang served at SDIC Securities Co., Ltd. (formerly known as Essence Securities Co., Ltd.) (“**SDIC Securities**”), where he held positions including Business Director and Executive General Manager of the Investment Banking Committee. During his tenure with SDIC Securities, he also served as a member of its equity financing internal review committee. Mr. Zhang has a proven track record in capital market operations, having led or participated in the initial public offerings and major asset restructuring of numerous listed companies. Before his tenure at SDIC Securities, Mr. Zhang worked at Huatai United Securities Co., Ltd. (“**Huatai United Securities**”) from February 2008 to May 2015, advancing from Project Manager to Business Director. He concurrently served on the project initiation and internal review committees of Huatai United Securities. During his tenure with Huatai United Securities, he managed various corporate bond issuance and private placement projects.

Mr. Zhang graduated from Beijing Normal University in 2006 with a Bachelor of Management degree in Human Resource Management and a dual Bachelor of Economics degree in International Economics and Trade. He subsequently obtained a Master of Economics degree from The University of Hong Kong in 2007. Mr. Zhang was a Registered Sponsor Representative in the People's Republic of China from September 2015 to January 2026.

The Company has entered into a service contract with Mr. Zhang for a term of three years, and he is subject to retirement and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Zhang is entitled to receive a monthly salary of RMB60,000 and an annual director's fee of HK\$63,000 under his service contract. In addition, he is also eligible to receive performance-related discretionary bonus to be determined by the Board. His emoluments were determined by the Board based on the recommendations of the Remuneration Committee of the Company and with reference to his experience, responsibilities with the Company, current market practices and the remuneration policy of the Company.

As at the date of this announcement, save as disclosed above, Mr. Zhang: (i) does not have any other interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other positions with the Company and/or other members of its subsidiaries; (iii) does not have any relationship with any director, senior management, substantial or controlling shareholder of the Company (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")); and (iv) has not held any other directorships in the past three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed in this announcement, Mr. Zhang confirmed that there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, and there are no other matters concerning his appointment that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Mr. Zhang on his appointment.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 March 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.